Advertisement

Diseases of the Colon & Rectum

, Volume 40, Issue 4, pp 451–456 | Cite as

Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis

A case control study
  • Karin Lundqvist
  • Ulrika Broomé
Original Contributions

Abstract

PURPOSE: A small group of patients with ulcerative colitis (UC) also suffer from primary sclerosing cholangitis (PSC). Genetic and immunologic differences exist between UC patients with and without concomitant PSC. Furthermore, UC patients with PSC are more prone to developing colonic dysplasia/aneuploidy compared with patients with UC only. Because colonic disease activity and treatment with sulfasalazine have been found to be of independent importance for development of colonic carcinoma in UC, this study aims to determine if differences exist concerning colonic disease activity in UC patients with and without PSC. METHODS: Twenty-nine PSC patients with total colitis were matched to two UC patients with total colitis but without liver disease. Case records and questionnaires were used to gain information on pharmacologic treatment and disease activity. RESULTS: Observation time was 20 (PSC group) and 23 years (UC only). Number of patients taking prophylactic treatment did not differ between groups. Patients with UC only had received treatment with systemic and local corticosteroids significantly more often than UC patients with PSC (P< 0.05 andP< 0.02). Patients with UC only were hospitalized because of colonic activity significantly more often (P< 0.02). Number of patients undergoing colectomy because of disease activity or number of patients with chronic continuous symptoms did not differ between the two groups. CONCLUSION: UC in patients with PSC runs a milder course than UC in patients without this complication, although the number of patients taking prophylactic treatment was the same. If lower disease activity reflects differences in pathogenesis of UC in patients with PSC or if it can explain increased risk to develop colonic malignancy in patients with both PSC and UC needs further elucidation.

Key words

Corticosteroids Colectomy Sulfasalazine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ 1955;2:1041–8.Google Scholar
  2. 2.
    Daniels GE. Psychiatric factors in ulcerative colitis. Gastroenterology 1948;10:59–62.Google Scholar
  3. 3.
    Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187–9.PubMedGoogle Scholar
  4. 4.
    Riley SA, Mani VJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990;31:179–83.PubMedGoogle Scholar
  5. 5.
    Olsson R, Danielsson A, JÄrnerot G,et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319–23.PubMedGoogle Scholar
  6. 6.
    Broomé U, Glaumann H, Hellers G, Sörstad J, Nillson B, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow-up study in the county of Stockholm. Gut 1994;35:84–9.PubMedGoogle Scholar
  7. 7.
    Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;80:200–6.Google Scholar
  8. 8.
    Thorpe ME, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut 1967;8:435–48.PubMedGoogle Scholar
  9. 9.
    Aadland E, Schrumpf E, Fausa O,et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655–64.PubMedGoogle Scholar
  10. 10.
    Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982;17:187–91.PubMedGoogle Scholar
  11. 11.
    Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part IV. Carcinoma of the colon. Gut 1964;5:15–22.Google Scholar
  12. 12.
    Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877–80.PubMedGoogle Scholar
  13. 13.
    Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis-evidence for increased neoplastic potential. Hepatology 1995;22:1404–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H-O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994;107:117–20.PubMedGoogle Scholar
  15. 15.
    Chapman RW, Arborgh BA, Rhodes JM,et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980;21:870–7.PubMedGoogle Scholar
  16. 16.
    Evans JG, Acheson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut 1965;6:311–24.PubMedGoogle Scholar
  17. 17.
    Nordenvall B, Broström O, Berglund M, Monsén U, Sörstad J, Hellers G. Incidence of ulcerative colitis in Stockholm county 1955–1979. Scand J Gastroenterol 1985;20:311–24.Google Scholar
  18. 18.
    Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiological study. Gut 1990;31:329–33.PubMedGoogle Scholar
  19. 19.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625–9.PubMedGoogle Scholar
  20. 20.
    Seo M, Okada M, Yao T, Ueki M, Arima S, Okumara M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–6.PubMedGoogle Scholar
  21. 21.
    McFarlane IG. Autoreactivity against biliary tract antigens in primary biliary cirrhosis. Mol Aspects Med 1985;8:249–67.CrossRefPubMedGoogle Scholar
  22. 22.
    Minuk GY, Angus M, Brickman CM,et al. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985;88:166–70.PubMedGoogle Scholar
  23. 23.
    Zetterquist H, Broome U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992;33:942–6.PubMedGoogle Scholar

Copyright information

© American Society of Colon and Rectal Surgeons 1997

Authors and Affiliations

  • Karin Lundqvist
    • 1
  • Ulrika Broomé
    • 1
  1. 1.Department of Gastroenterology and HepatologyHuddinge University Hospital, Karolinska InstituteStockholmSweden

Personalised recommendations